Literature DB >> 20679526

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Steven M Kornblau1, David McCue, Neera Singh, Wenjing Chen, Zeev Estrov, Kevin R Coombes.   

Abstract

The role of circulating cytokines and chemokines (C&Ckine) in activating signal transduction in leukemic cells is incompletely defined. We hypothesized that comprehensive profiling of C&Ckine expression in leukemia would provide greater insight compared with individual analyses. We used multiplex array technology to simultaneously measure the level of 27 C&Ckines in serum from 176 acute myelogenous leukemia (AML) and 114 myelodysplastic syndrome (MDS) patients and 19 normal controls. C&Ckine levels in AML and MDS differed significantly from normal controls (5 higher, 13 lower) but were similar to each other for 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in AML and vascular endothelial growth factor A higher in MDS. Levels did not correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytognetic abnormalities in AML. Individually, few cytokines had any correlation with response or survival. In newly diagnosed AML, 8 C&Ckine signatures, distinct from the normal control signature, were observed. These signatures had prognostic impact, affecting remission, primary resistance, relapse rates, and overall survival, individually (P = .003) and in multivariable analysis (P = .004). These patterns suggest specific therapeutic interventions to investigate in subsets of AML patients. In conclusion, C&Ckine expression in AML and MDS differs from normal, is similar with one another, and forms recurrent patterns of expression with prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679526      PMCID: PMC4081283          DOI: 10.1182/blood-2010-01-262071

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Authors:  Katerina E Panteli; Eleftheria C Hatzimichael; Paraskevi K Bouranta; Afroditi Katsaraki; Konstantinos Seferiadis; Justin Stebbing; Konstantinos L Bourantas
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

Review 2.  Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB.

Authors:  Bharat B Aggarwal; Yasunari Takada
Journal:  Cancer Treat Res       Date:  2005

3.  Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.

Authors:  Faina Linkov; Alex Lisovich; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; Brian Nolen; Matthew Winans; William Bigbee; Jill Siegfried; Anna Lokshin; Robert L Ferris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

4.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.

Authors:  Alvaro Aguayo; Hagop M Kantarjian; Elihu H Estey; Francis J Giles; Srdan Verstovsek; Taghi Manshouri; Christy Gidel; Susan O'Brien; Michael J Keating; Maher Albitar
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

5.  Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.

Authors:  Jong Gwang Kim; Sang Kyun Sohn; Dong Hwan Kim; Jin Ho Baek; Nan Young Lee; Jang Soo Suh; Shung-Chull Chae; Kun Soo Lee; Kyu Bo Lee
Journal:  Leuk Lymphoma       Date:  2005-06

6.  Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor.

Authors:  David Stroncek; Stefanie Slezak; Hanh Khuu; Christopher Basil; John Tisdale; Susan F Leitman; Francesco M Marincola; Monica C Panelli
Journal:  Exp Hematol       Date:  2005-10       Impact factor: 3.084

7.  Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome.

Authors:  F Vinante; A Rigo; C Tecchio; L Morosato; G Nadali; M M Ricetti; M Krampera; E Zanolin; F Locatelli; H Gallati; M Chilosi; G Pizzolo
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

Review 8.  IL-4, IL-10 and IL-13 in acute myelogenous leukemia.

Authors:  O Bruserud
Journal:  Cytokines Cell Mol Ther       Date:  1998-09

Review 9.  GM-CSF in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Trends Immunol       Date:  2002-08       Impact factor: 16.687

10.  Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.

Authors:  Z Estrov; R A Black; P R Sleath; D Harris; Q Van; R LaPushin; E H Estey; M Talpaz
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

View more
  65 in total

1.  Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.

Authors:  Anthony D Sung; Shekeab Jauhari; Sharareh Siamakpour-Reihani; Arati V Rao; Janet Staats; Cliburn Chan; Everett Meyer; Vijayakrishna K Gadi; Andrew B Nixon; Jing Lyu; Jichun Xie; Lauren Bohannon; Zhiguo Li; Christopher S Hourigan; Laura W Dillon; Hong Yuen Wong; Rebecca Shelby; Louis Diehl; Carlos de Castro; Thomas LeBlanc; Danielle Brander; Harry Erba; Ahmed Galal; Alexandra Stefanovic; Nelson Chao; David A Rizzieri
Journal:  Am J Hematol       Date:  2020-03-30       Impact factor: 10.047

2.  Are serum cytokines sensitive and specific enough to prognosticate in aspergillosis?

Authors:  Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

3.  IL-1β-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors.

Authors:  Chiara Vitale; Paolo Ambrosini; Elisa Montaldo; Filippo Ballerini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

4.  The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.

Authors:  Meng-Ya Si; Zhi-Cheng Fan; Ya-Zhen Li; Xiao-Lan Chang; Qing-Dong Xie; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2015-01-30       Impact factor: 4.130

Review 5.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

6.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

Review 7.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

8.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

9.  Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome.

Authors:  Anacélia Gomes de Matos; Howard Lopes Ribeiro Junior; Daniela de Paula Borges; Bruno Memória Okubo; Juliana Cordeiro de Sousa; Maritza Cavalcante Barbosa; Marilena Facundo de Castro; Romélia Pinheiro Gonçalves; Ronald Feitosa Pinheiro; Silvia Maria Meira Magalhães
Journal:  Med Oncol       Date:  2017-08-30       Impact factor: 3.064

10.  Homeobox protein HB9 binds to the prostaglandin E receptor 2 promoter and inhibits intracellular cAMP mobilization in leukemic cells.

Authors:  Sarah Wildenhain; Deborah Ingenhag; Christian Ruckert; Özer Degistirici; Martin Dugas; Roland Meisel; Julia Hauer; Arndt Borkhardt
Journal:  J Biol Chem       Date:  2012-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.